Trending now:  
Semaglutide’s impact on obesity-related heart failure with preserved ejection fraction
NOAH-AFNET 6: Oral anticoagulation & atrial high rate episodes
ESC 2023 Highlights
ESC Congress 2023 Highlights
What to expect at ESC Congress 2023

Content for healthcare professionals only

News |

ESC Congress 2023 Highlights

29 Aug 2023
ESC 2023 Highlights

The European Society of Cardiology (ESC) held its 46th annual congress August 25-29, 2023 in Amsterdam, Netherlands. Here is our curated list of the top 13 sessions.

STEP HFpEF (NCT04788511) explored if semaglutide could be used to target obesity-related heart failure with preserved ejection fraction (HFpEF). Investigators randomized 529 adult patients with HFpEF and obesity to receive either once weekly semaglutide (n=263) or placebo (n=266). Patients receiving semaglutide showed a greater change in Kansas City Cardiomyopathy Questionnaire clinical summary scores at 52 weeks than placebo. Semaglutide was also associated with a greater change in body weight than placebo. Patients taking semaglutide showed greater reductions in C-reactive protein levels than patients on placebo. Patients taking semaglutide also improved their 6-minute walk distance (6MWD) to a greater degree than patients on placebo.

NOAH-AFNET 6 (NCT02618577) explored if edoxaban could prevent stroke or cardiovascular (CV) death in patients with atrial high rate episodes. A composite of CV death, stroke or systemic embolism comprised the primary endpoint. A composite of death from any cause or major bleeding comprised the....

To read full highlights article please login or sign up as a member.

Share:

Related Topics

Related Articles